Please login to the form below
COPD
This page shows the latest COPD news and features for those working in and with pharma, biotech and healthcare.
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... He added that, despite the encouraging data in COPD, this
Latest news
-
Policy and public health: ML and AI in healthcare
If you smoke ten packs of cigarettes per day, you will likely suffer from emphysema or COPD or some other respiratory illness.
-
GSK seeks EU approval for Trelegy in adult asthma patients
Triple respiratory drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is already approved in the EU and US for use in chronic obstructive pulmonary disease (COPD) patients, although GSK is now keen ... The expansion into asthma is also
-
GSK licenses its tuberculosis vaccine to Gates MRI
It’s in-house R&D in this area is focused on vaccines against respiratory syncytial virus (RSV), bacteria that contribute to chronic obstructive pulmonary disease (COPD) and a new meningitis
-
Pharma’s race to digital
detects chronic obstructive pulmonary disease (COPD) in older adults.
-
Nucala works in rare inflammatory disease, says GSK
COPD). 13th November 2019.
More from news
Approximately 71 fully matching, plus 224 partially matching documents found.
Latest Intelligence
-
AI: the smart money is on the smart thinking
The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and
-
The impact of COVID-19 on clinical trials
Patient populations – trials with vulnerable populations (eg, the elderly, the immunocompromised, patients with pulmonary conditions such as COPD).
-
A snapshot of… Enterprise Therapeutics
of infection in respiratory diseases such as cystic fibrosis (CF) and COPD. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as COPD, severe asthma, bronchiectasis and
-
GSK forges ahead with its dynamic COPD and asthma portfolio
A landmark year of discovery and development in COPD brings hope to millions of patients. ... The emergence of eosinophil counts as a biomarker in COPD has been helpful.
-
20 for 2020 – Five pharma companies to watch
There are also potential approvals for anifrolumab in lupus and PT010 in chronic obstructive pulmonary disease (COPD).
More from intelligence
Approximately 0 fully matching, plus 43 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
in development for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. ... for the maintenance treatment of COPD.”.
-
Vikas Sinha joins Verona as non-executive director
A potential first-in-class treatment for chronic obstructive pulmonary disease (COPD), Verona Pharma's RPL554 is being tested as a nebulised maintenance treatment for patients with moderate to severe disease.
-
GSK's Dr Brett Haumann takes up chief medical officer role at Circassia
Most recently these saw him serve as VP and medicines development leader responsible for the late-stage development of once-daily inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Covid-19 drives change in long-term conditions management
A key resource in this field is myCOPD - a specialist self-care app designed and built by COPD experts, and externally peer-reviewed by leading NHS consultants.
-
Addressing Climate Impact: The Healthcare Paradox
Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction.
-
RWE Blog 1: Real-world challenges and real-world data
In a review of 870 out-patients with asthma and/or Chronic Obstructive Pulmonary Disease (COPD), only one in 20 asthma patients and one in six COPD patients met the typical
-
Innovative pricing and contracting options
For instance, the online-based project launched in 2013 by AstraZeneca and patient engagement firm Exco InTouch, Me&myCOPD, aims to provide chronic obstructive pulmonary disease (COPD) patients with disease information,
-
A new vision for tackling key illnesses
It will be run by multi-disciplinary teams using digital tools, such as My COPD, which is a toolkit for Clinical Commissioning Groups (CCGs).
More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Moderna inks R&D agreements with Vertex and Chiesi
- Shionogi's Gram-negative antibiotic launches in the UK
- Eli Lilly reports first results for COVID-19 targeting antibody
- Live Webinar: Medical Modeling in Virtual Reality
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
